Gilead Sciences (GILD) Other Accumulated Expenses (2011 - 2026)

Gilead Sciences has reported Other Accumulated Expenses for 12 years, with the latest figure at $3.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 26.35% year-over-year to $3.4 billion; the trailing twelve-month figure through Mar 2026 stood at $3.4 billion (down 26.35% YoY), and the FY2025 full-year result was $4.0 billion, down 27.65% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $3.4 billion, down from $4.0 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $5.9 billion in Q3 2023, with the low at $3.4 billion in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $4.6 billion across 5 years, with a median of $4.5 billion in 2022.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses increased 12.01% — and 2025, when it slipped 27.65%.
• Gilead Sciences' Other Accumulated Expenses stood at $4.6 billion in 2022, then rose by 12.01% to $5.1 billion in 2023, then increased by 6.51% to $5.5 billion in 2024, then declined by 27.65% to $4.0 billion in 2025, then fell by 14.01% to $3.4 billion in 2026.
• The last three Other Accumulated Expenses figures came in at $3.4 billion (Q1 2026), $4.0 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.